Company Fact Sheet

May 2021 (Data as of 30 April 2021)

Unique investments in private and listed life science companies

Profile

ł	Swiss investment compa nolding a global portfolio of er			ies		
Unique Swiss-based, permanent capital, healthcare- dedicated investment vehicle to invest in both private and public companies	Investments focusing on growth companies in the biotech, medical technology, diagnostic and health IT sectors	Portfolio com achieved proof c and major clin regulatory mil before inves	of concept ical and estones	Ex Dedicate teams for p public equi industry external bu	rivate eq ty with a networl	uity and a global c and
HBM strategy validated by over 60 trade sales or IPOs since 2010	Lower risk Lower volatility of NAV through private equity and partial hedging of market risk and USD currency risk	Dividen Attractive divide with 3-5% yield t	end policy	Establis and SIX So listed since 3′500 s	wiss Exc	hange- ith over
Key Figures (in CHF)		Performance				
Total Assets Net Assets (NAV) Market Capitalisation	2'245 million 2'089 million 2'283 million	<u>Return</u> NAV Share Price	-2.9% 2	YTD 3y p.a. 2.4% 23.7% 7.5% 30.9%	<u>5y p.a.</u> 18.3% 29.2%	<u>10y p.a.</u> 19.0% 22.6%
Share Price NAV per share Premium	328.00 300.21 9.3%	<u>Return by Year</u> NAV Share Price	2.4% 36	2020 2019 5.7% 33.0% 0.5% 48.0%	2018 9.9% 21.8%	<u>2017</u> 25.8% 40.5%
LTM daily trading volume Number of issued shares Number of shareholders	8'560 shares, ~2.8 million 6.96 million ~ 3'500	<u>Dividend</u> in CHF Yield in % (Total return, incl	t.b.d.	2020 2019 7.70 7.50 4.1% 4.4% butions)	<u>2018</u> 7.00 4.9%	<u>2017</u> 5.80 5.2%
250	ncare Investments Share Price	—— НВМ	Healthcare In			Amm
300 — MSCI World 300 — NBI1ndex 250 — —	J Healthcare		World 		frante	
200 150 100		Martin Martin	man man	A and		Atam
50	017 2018	2019		2020		2021
Investment Approach		Reasons to Inv	/est			


Investment Approach


- Fundamental long with private and public healthcare investments
- Focus on companies with innovative platforms and drug candidates
- Bottom-up selection of investments with solid long-term growth potential
- HBM takes an active role and assumes entrepreneurial responsibility together with the management team

Reasons to Invest

- Access to a diversified portfolio of private and listed healthcare companies with value increasing potential
- Global orientation with focus on the US, but increasing allocation in emerging markets such as China and India
- Closed-end structure allows optimum exploitation of the value-increasing potential of healthcare companies
- Lower correlation to public market portfolios thanks to the substantial private capital allocation

Portfolio Summary May 2021





In CHF million

Data as of 30 April 2021, in % of total assets of CHF 2'245 million

Data as of 31 March 2021

Portfolio Summary May 2021

Largest Investments

Company	Core Business	Phase of Lead Product	Ticker	Market Capitalisation (CHF m)	Owner- ship (%)	Book Value (CHF m)	% of Total Assets
ROUSTROLL BOTICST	Synthetic biology (long chain diacids, carbohydrates, special enzymes, green nylon)	Market	688065 CH (ex private)	4′675	7.1	286.7 ¹⁾	12.8
HB HARMONY BIOSCIENCES, LLC	Drug for the treatment of narcolepsy (with and without cataplexy)	Market	HRMY (ex private)	1′522	8.2	124.2	5.5
bicatla	Developing antibody-based therapeutics for the treatment of solid tumor cancers	Phase II	BCAB (ex private)	1′458	5.3	77.7	3.5
Swixx © BioPharma	Full representation of biopharma companies in central and eastern Europe	Market	Private	202*	28.8	58.0	2.6
ALX ¢ncology	Developing immuno- oncology therapies	Phase I	ALXO (ex private)	2′306	2.4	55.3	2.5
mAbs	Developing novel antibody therapeutics for oncology targets	Market	YMAB (ex private)	1′196	4.5	54.2	2.4
NEURELIS	Nasal spray for the treatment of epileptic seizures	Market	Private	486*	10.6	51.3	2.3
argenx	Drugs for autoimmune and cancer diseases	Phase III	ARGX	13′193	0.4	47.3	2.2
SpringWorks	Pipeline of targeted oncology programs	Phase III	SWTX (ex private)	3′214	1.4	44.4	2.0
Instil Bio	Developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers	Phase I	TIL (ex private)	2′404	1.7	41.1	1.8
biohaven	Drugs for treatment of neurological and neuropsychiatric diseases (including rare diseases)	Market	BHVN	4′350	0.8	34.8	1.6
zyme works	Discovery and development of next- generation multifunctional biotherapeutics, initially focused on the treatment of cancer	Phase I	ZYME	1′370	2.3	31.0	1.4

1) Deferred tax on capital gain and VAT based on difference between potential selling and IPO price not included; lock up discount for 3 years starting August, 2020 reflected; * Implied company valuation (for private companies)

Company Fact Sheet May 2021

Unique investments in private and listed life science companies

Legal statusClosed-ended, listed investment company under laws of Switzerland, nextments held through fully owned subsidiary in the Cayman Islands.ListingSIX Swiss Stock Exchange, ZurichTickerHBMNCinding liquidityChoil 2627250Reporting correncySwiss Francs (CHF)Reporting requery NAV colubitSix Francs (CHF)Financial year andSuffer Strands (CHF)Financial year andSix Francs (CHF)Financial year andSix Francs (CHF)Financial year andSix Francs (CHF)Financial year andSix Strands (CHF)Financial year and strands (CHF)Six Strands (CHF)Financial year and strands (CHF)Six Strands (CHF)Financial year and strands (CHF)Six Strands (CHF)Financial year and yea		
TickerHBMNISIN NumberCH0012627250Trading liquidityDaily, average daily trading volume of 8'560 shares (~CHF 2.8 million)Reporting currencySwiss Francs (CHF)Reporting frequency / NAV calculationQuarterly financial reporting; Monthly fact sheet; Bi-monthly NAV publication (mid- and end of month), Ad-hoc media releases for price sensitive informationFinancial year end31 MarchInvestment advisorHBM Partners AG, Zug (Switzerland)Prime Broker / CustodianMorgan Stanley & Co International plc., London (UK); Bank of America Merrill Lynch , San Francisco; Citic Securities, ShanghaiAuditorErnst & Young Ltd., ZurichInception Date0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Legal status	
IsinISIN NumberCH0012627250Trading liquidityDaily, average daily trading volume of 8'560 shares (-CHF 2.8 million)Reporting currencySwiss Francs (CHF)Reporting frequency / NAV calculationQuarterly financial reporting; Monthly fact sheet; Bi-monthly NAV publication (mid- and end of month), Ad-hoc media releases for price sensitive informationFinancial year end31 MarchInvestment advisorHBM Partners AG, Zug (Switzerland)Prime Broker / CustodianMorgan Stanley & Co International plc., London (UK); Bank of America Merrill Lynch, San Francisco; Citic Securities, ShanghaiAuditorErnst & Young Ltd., ZurichInception Date0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Listing	SIX Swiss Stock Exchange, Zurich
Trading liquidityDaily, average daily trading volume of 8'560 shares (-CHF 2.8 million)Reporting currencySwiss Francs (CHF)Reporting frequency / NAV calculationQuarterly financial reporting; Monthly fact sheet; Bi-monthly NAV publication (mid- and end of month), Ad-hoc media releases for price sensitive informationFinancial year end31 MarchInvestment advisorHBM Partners AG, Zug (Switzerland)Prime Broker / CustodianMorgan Stanley & Co International plc., London (UK); Bank of America Merrill Lynch , San Francisco; Citic Securities, ShanghaiAuditorErnst & Young Ltd., ZurichInception Date12 July 2001Management fee0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Ticker	HBMN
Reporting currencySwiss Francs (CHF)Reporting frequency / NAV calculationQuarterly financial reporting; Monthly fact sheet; Bi-monthly NAV publication (mid- and end of month), Ad-hoc media releases for price sensitive informationFinancial year end31 MarchInvestment advisorHBM Partners AG, Zug (Switzerland)Prime Broker / CustodianMorgan Stanley & Co International plc., London (UK); Bank of America Merrill Lynch , San Francisco; Citic Securities, ShanghaiAuditorErnst & Young Ltd., ZurichInception Date12 July 2001Management fee0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	ISIN Number	CH0012627250
Reporting frequency / NAV calculationQuarterly financial reporting; Monthly fact sheet; Bi-monthly NAV publication (mid- and end of month), Ad-hoc media releases for price sensitive informationFinancial year end31 MarchInvestment advisorHBM Partners AG, Zug (Switzerland)Prime Broker / CustodianMorgan Stanley & Co International plc., London (UK); Bank of America Merrill Lynch , San Francisco; Citic Securities, ShanghaiAuditorErnst & Young Ltd., ZurichInception Date12 July 2001Management fee0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Trading liquidity	Daily, average daily trading volume of 8'560 shares (~CHF 2.8 million)
Reporting frequency / NAV calculation(mid- and end of month), Ad-hoc media releases for price sensitive informationFinancial year end31 MarchInvestment advisorHBM Partners AG, Zug (Switzerland)Prime Broker / CustodianMorgan Stanley & Co International plc., London (UK); Bank of America Merrill Lynch , San Francisco; Citic Securities, ShanghaiAuditorErnst & Young Ltd., ZurichInception Date12 July 2001Management fee0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Reporting currency	Swiss Francs (CHF)
Investment advisorHBM Partners AG, Zug (Switzerland)Prime Broker / CustodianMorgan Stanley & Co International plc., London (UK); Bank of America Merrill Lynch , San Francisco; Citic Securities, ShanghaiAuditorErnst & Young Ltd., ZurichInception Date12 July 2001Management fee0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Kontact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Reporting frequency / NAV calculation	Quarterly financial reporting; Monthly fact sheet; Bi-monthly NAV publication (mid- and end of month), Ad-hoc media releases for price sensitive information
Prime Broker / CustodianMorgan Stanley & Co International plc., London (UK); Bank of America Merrill Lynch, San Francisco; Citic Securities, ShanghaiAuditorErnst & Young Ltd., ZurichInception Date12 July 2001Management fee0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Financial year end	31 March
Prime Broker / CustodianLynch , San Francisco; Citic Securities, ShanghaiAuditorErnst & Young Ltd., ZurichInception Date12 July 2001Management fee0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Investment advisor	HBM Partners AG, Zug (Switzerland)
Inception Date12 July 2001Management fee0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Prime Broker / Custodian	
Management fee0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Auditor	Ernst & Young Ltd., Zurich
Management reequarterly at the beginning of a quarter.Performance fee15% of increase of the net asset value above the high water mark, calculated paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Inception Date	12 July 2001
Paid annually based on the audited year-end net asset value, provided that value increase is more than 5 per cent.High water markNAV of CHF 327.77Contact informationHBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Management fee	
Contact information HBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland	Performance fee	paid annually based on the audited year-end net asset value, provided that
	High water mark	NAV of CHF 327.77
	Contact information	

Disclaimer

This is an advertising document. This document is intended to be for information purposes only and should not be construed as an offer or solicitation for the purchase of this product.

Information herein is believed to be reliable but HBM does not warrant its completeness or accuracy. HBM has expressed its own views in this document and these may change.

Past performance is not a reliable indicator or guarantee of future results. All performance data are based on net performance and take no account of commissions, fees or other costs charged when units are issued and redeemed. Prices of shares and the income from them may fall as well as rise and investors may not get back the amount originally invested. An investment entails risks, which are fully described in the offering documents.

Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions. The data provider and HBM shall have no liability in connection with third party data.

03/2021